赛诺菲喜保宁安全性怎么样？

(Vigabatrin tablets) is a chemical structural analog of the natural neurotransmitter gamma-aminobutyric acid (GABA). It was approved by the US FDA for marketing in August 2009. It is the only drug approved by the FDA for the treatment of infantile spasms. In addition, the drug can also be used to assist in the treatment of partial seizures in refractory complex epilepsy. So, how safe is Sanofi Vigabatrin?

As one of the growth platforms for sustainable development, Sanofi's R&D department is committed to providing treatment solutions for patients. It has always inherited a long history and continued to forge ahead. The therapeutic effect of Vigabatrin produced by Sanofi is relatively obvious. In terms of safety, the adverse drug reactions caused by Sanofi Vigabatrin are mainly visual field narrowing, which is often asymptomatic bilateral concentric visual field constriction. After it was first reported by clinicians, it attracted widespread attention. In this regard, patients also need to pay high attention during actual medication to avoid serious adverse events.

According to literature reports, the incidence of visual field narrowing caused by Vigabatrin (vigabatrin tablets) ranges from 14% to 92%. Differences in clinical standards, choice of visual field examination methods, dosage, and treatment cycles among various studies may be the reason for the large differences in study results. The visual field narrowing caused by vigabatrin is a peripheral visual field narrowing. The visual field shrinks from the periphery to the center. The macula is relatively less affected, so it is often difficult for patients to detect it themselves. Some pediatric patients also have abnormal color discrimination and decreased visual acuity.

Pharmacoepidemiological studies have found that this type of visual field narrowing is more likely to occur in men, and the incidence is positively correlated with the cumulative dosage of vigabatrin tablets. It is estimated that the risk of visual field constriction is 4% for patients who take a cumulative dose of 1,000g, while the risk for patients who take a cumulative dose of 3,000 to 5,000g is 75%. The onset of visual field narrowing can range from 6 weeks to 10 years after taking the medication.

Recommended hot articles: /newsDetail/93720.html